The future of behavioral health may look very different than it does today. A major step forward came in October 2020 when NYU Langone Health and MindMed, a psychedelic medicine biotech company, announced the launch of a new psychedelic medicine research training program. Designed to prepare psychiatrists and clinical investigators for the next generation of therapies, the program focuses on training experts to study and eventually deliver psychedelic-assisted treatments for substance use disorders (SUDs) and other mental health challenges.
This groundbreaking partnership signals the increasing legitimacy and momentum behind psychedelic therapies in mainstream medicine, especially within behavioral health.
A Landmark Collaboration
NYU Langone Health, based in New York City, is one of the nation’s leading academic medical centers. Its Department of Psychiatry at the NYU Grossman School of Medicine has already been a pioneer in researching psychedelic-assisted therapies for conditions like addiction, anxiety, and depression.
Meanwhile, MindMed has emerged as one of the most visible companies in the psychedelic medicine space. The biotech firm develops treatments derived from psychoactive compounds, with a particular emphasis on addressing addiction and psychiatric disorders. Importantly, MindMed has a history of collaboration with NYU dating back to 2009.
The new Psychedelic Medicine Research Training Program at NYU represents the next evolution of their relationship. With MindMed committing $5 million over the next five years, the initiative is poised to transform how mental health and substance use treatment are studied, understood, and eventually practiced in the clinical setting.
The Purpose Behind the Program
At its core, the training program aims to address a pressing challenge: how to safely and effectively integrate psychedelic therapies into behavioral health care.
As MindMed co-founder and co-CEO JR Rahn explained, “What we want to do with them is ultimately figure out how we’re going to end up deploying all these medicines to patients in the future. How do you train a healthcare community and a psychiatric community that has never really worked with these medicines before?”
Psychedelic-assisted therapies hold enormous promise, but most clinicians have little to no experience using these substances in a therapeutic context. That’s where this program comes in — equipping psychiatrists and clinical researchers with the knowledge, training, and ethical frameworks they need to responsibly advance the field.
A Focus on Research and Evidence
While there’s widespread enthusiasm about psychedelic-assisted therapies, both NYU Langone and MindMed emphasize that more research is needed before these treatments can be scaled to the general public.
The training program will not only recruit and train new investigators but also prioritize rigorous, evidence-based studies to clarify the best practices for psychedelic medicine.
Dr. Charles R. Marmar, chair of the Department of Psychiatry at the NYU Grossman School of Medicine, underscored this point:
“MindMed’s funding meets an important need for recruiting more clinical investigators and psychiatrists to the expanding and promising areas of psychedelic assisted therapies and psychedelic inspired medicines, which can help so many people suffering from addiction and other mental illnesses.”
By strengthening the research pipeline, NYU Langone hopes to generate the data needed to guide safe, effective treatment protocols and shape regulatory approval in the years ahead.
Spotlight on Substance Use Disorders
Initially, the NYU Langone Psychedelic Medicine Research Training Program will focus heavily on substance use disorders. This emphasis reflects both the urgency of the addiction crisis and the promising signals from early psychedelic studies.
For example, research has shown that certain psychedelic compounds may help reduce cravings, interrupt harmful patterns of thought and behavior, and foster breakthroughs in therapy. MindMed itself is preparing to enter Phase 2 clinical trials for an opioid use disorder treatment derived from psychoactive substances.
As Rahn noted, “The grander vision here is to scale this, but we need to start somewhere.” Starting with addiction treatment makes sense given the enormous need: in the U.S. alone, millions of people struggle with opioid misuse, alcohol dependence, and other SUDs, and traditional treatments don’t always succeed.
Toward a Center for Psychedelic Medicine
Beyond the immediate training program, NYU Langone and MindMed have larger ambitions. The two organizations envision establishing a full-fledged Center for Psychedelic Medicine at NYU. Such a center would serve as a hub for education, research, and clinical practice, setting standards for the field and pushing the science forward.
However, more funding is required to bring that vision to life. MindMed’s initial $5 million investment is a strong start, but long-term sustainability will depend on additional contributions, grants, and institutional support.
If successful, the Center could put NYU Langone at the forefront of psychedelic medicine globally, influencing how psychiatry evolves in the 21st century.
The Bigger Picture: Psychedelics in Behavioral Health
The launch of this program highlights a broader trend: the mainstreaming of psychedelics in medicine. Just a decade ago, psychedelic research was fringe, limited by stigma and strict drug policies. Today, some of the world’s most respected academic institutions — including Johns Hopkins, Imperial College London, and now NYU Langone — are investing in the field.
Why? Because preliminary studies have shown remarkable outcomes for conditions that often resist conventional treatments, including:
- Depression
- Post-Traumatic Stress Disorder (PTSD)
- Anxiety Disorders
- Substance Use Disorders
- End-of-Life Existential Distress
The FDA has even granted Breakthrough Therapy designation to certain psychedelic-based treatments, accelerating their path to approval.
At the same time, experts caution that psychedelic medicine is not a magic bullet. Careful regulation, ethical oversight, and high-quality training are essential to ensure patient safety and maximize therapeutic benefits.
Challenges Ahead
Despite the promise, challenges remain. These include:
- Regulatory Hurdles: Many psychedelics remain classified as Schedule I substances under U.S. law, limiting access and research
- Public Perception: Lingering stigma from the “War on Drugs” era may slow adoption among some patients and providers
- Clinical Training: Developing standardized training protocols for psychiatrists, therapists, and researchers is still a work in progress
- Equity and Access: Ensuring these therapies are available to all communities — not just those who can afford them — will be crucial
Programs like the one at NYU Langone are designed to tackle these issues head-on, laying the foundation for a responsible rollout.
A Vision for the Future
The partnership between NYU Langone Health and MindMed represents a turning point for behavioral health. By investing in research, training, and clinical development, they are helping to prepare the psychiatric community for a future where psychedelic-assisted therapies are a standard option in the treatment toolbox.
As Rahn put it, the goal is not only to study the medicines but also to train the therapists and psychiatrists who will deliver them — potentially even in patients’ homes one day, provided safety and efficacy are proven.
In the end, the program embodies both scientific rigor and human hope: the belief that by exploring new frontiers in medicine, we can find better ways to help people heal from addiction, trauma, and mental illness.
Conclusion
With its $5 million commitment and a history of collaboration, MindMed has joined forces with NYU Langone Health to launch one of the most forward-thinking initiatives in modern psychiatry. The Psychedelic Medicine Research Training Program will shape the next generation of psychiatrists, clinical investigators, and ultimately, patient care.
For those suffering from substance use disorders and other mental health conditions, the program offers something powerful: the possibility of new treatments, new hope, and a new era in behavioral health.
